Latest Conference Coverage

Living an Inspirational Life With Pediatric MS: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]

Expanding the Clinical Application of 2-Stage Models for Heterogenous Treatment Effects in MS: Carrie Hersh, DO, MSc

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]

Advantages of Wellness as a Therapy for Pediatric MS: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia, spoke about the wellbeing of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]

Beginning and Transitioning DMT in MS: Dalia Rotstein, MD, MPH

The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]

Gantenerumab Fails to Meet End Points in Initial GRADUATE Study Data

The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.

Establishing a Proof Of Concept Model to Improve MS Treatment Optimization: Carrie Hersh, DO, MSc

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]

NeurologyLive® Brain Games: November 13, 2022

ALS Research on Genetic Testing and Counseling Provides Evidence-Based Consensus Guidelines for Clinicians

Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.

Ability of Nuedexta to Improve Bulbar Function in Swallowing and Speech in ALS

James Wymer, MD, FAAN, discussed his presentation at the 2022 Annual NEALS meeting on improving speech and swallowing using Neudexta for patients with ALS.

Critical Takeaways, Learning Experiences From the Tofersen Trials in ALS: Timothy Miller, MD, PhD

The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]

Single Dose of AstroRx Transplantation Cells Shown to be Safe for ALS

A phase 1/2a clinical trial resulted in showing that a single dosing of AstroRx was safe and tolerable, at either a low or high dose, for patients with ALS.

Progress for Patients With Pediatric MS, Fingolimod's Risk-Benefit Profile: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke about her presentation at ECTRIMS 2022 on the treatment of pediatric MS. [WATCH TIME: 5 minutes]

Role of Tofersen Among Other Previously Approved ALS Therapies: Timothy Miller, MD, PhD

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]

Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MD

Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]

NurOwn Stromal Cell Therapy Continues to Show Positive Data in Less Severe ALS

After removing participants at higher risk of reaching a floor effect of the ALSFRS-R, those treated with NurOwn demonstrated a higher rate of clinical response and less function lost across 28 weeks than placebo.

Understanding Tofersen’s Impact on SOD1 ALS, Neurofilament Light: Timothy Miller, MD, PhD

The codirector of the ALS Center at Washington University School of Medicine in St. Louis discussed the long-term data of VALOR and its open-label extension assessing tofersen (Biogen) in SOD1 ALS. [WATCH TIME: 4 minutes]

Role of Serum Neurofilament Light in Predicting Neuromyelitis Optica Attacks: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on the importance of serum neurofilament light and how it can be used in the management of patients with NMOSD. [WATCH TIME: 3 minutes]

Need for Improving Measurements to Track Fatigue in MS

Federica Picariello, PhD, postdoctoral researcher, psychologist, King's College, London, spoke about fatigue mechanisms in patients with MS based on presentations from the 2022 ECTRIMS Congress.

Telehealth and Digital Measures May Assist With Monitoring MS Progression: Marisa McGinley, DO

The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke about her presentation from ECTRIMS 2022 on teleneurology and its utilization as a tool to make care more accessible to patients with MS. [WATCH TIME: 7 minutes]

Teleneurology Overcomes Health Disparities and Improves Accessibility in MS: Marisa McGinley, DO

The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke about her presentation on teleneurology being a beneficial healthcare tool for patients with MS at ECTRIMS 2022. [WATCH TIME: 7 minutes]

NeurologyLive® Brain Games: November 6, 2022

Digital Speech Biomarkers Show Promise in Recording Speech Function, Dysarthria in ALS

Those who reported higher ALSFRS-R speech scores at baseline had significantly higher diadochokinetic and word rate than those who reported speech disturbances, or lower scores.

Akt Activator IPL344 Demonstrates Safety, Signs of Efficacy in Phase 1/2 Study of ALS

By comparing results with pooled placebo groups from the PRO-ACT database, the data showed a 67% slower ALSFRS-R progression with IPL344.

Patient-Reported Outcomes Worsen as ALS Disease Progresses, Real-World Study Shows

On King’s staging systems, ALSAQ-5 scores increased from 24.6 at stage 1 to 62.1 at stage 4, whereas for Milano-Torino Staging systems, patients’ ALSAQ-5 scores increased from 43.2 at stage 0 to 80.7 at stage 3.

Long-Term Treatment of ALS Therapy Oral Edaravone Safe Up to 2 Years

Nearly one-fourth of the observed treatment-emergent adverse events were related to edaravone. Additionally, there were no serious TEAEs found, and TEAEs were mostly representative of ALS progression.

Racial Disparities Reported in the Initial Presentation of ALS

A retrospective study presented at the 2022 Annual NEALS Meeting reported health disparities in the initial presentation of Black patients with ALS in comparison with White patients.

Critical Aspects of Treatment During Postpartum in Patients with MS, NMOSD: Riley Bove, MD

The associate professor of neurology at the University of California, San Francisco, discussed the key points from an oral presentation at ECTRIMS 2022 on understanding postpartum for patients with MS and NMOSD. [WATCH TIME: 4 minutes]

RNS60 Shows Effects on Forced Vital Capacity, Not Functional Decline or Candidate Biomarkers

Treatment with RNS60 resulted in significantly slower rate of decline in FVC and eating and drinking domains of the ALSAQ-40 scale over a 24-week period.

Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]

Tegoprubart Demonstrates Safety, Target Engagement of ALS Markers in Phase 2 Study

Treatment with tegoprubart resulted in significant reductions of CD40L and CXCL13 levels that occurred after first infusion and sustained throughout the treatment period.